Do you want to read an article? Please log in or register.
A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer
Genitourinary Cancer
Related content
RECOMMENDED
Genitourinary Cancer
TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer
Clin Cancer Res.
De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY
doi: 10.1158/
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
Lung Cancer.
Koga T, Kobayashi Y, Tomizawa K, Suda K, Kosaka T, Sesumi Y, Fujino T, Nishino M, Ohara S, Chiba M, Shimoji M, Takemoto T, Suzuki M, Jänne PA, Mitsudomi T
doi: 10.1016/j.lungcan.
Genitourinary Cancer
Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer
JAMA Oncol.
Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, Vargas HA, Schöder H, Humm JL, Fine SW, Lewis JS, Solomon SB, Osborne JR, Veach D, Sawyers CL, Weber WA, Scher HI, Morris MJ, Larson SM
doi: 10.1001/
Breast Cancer
Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review
JAMA Oncol.
Kono M, Fujii T, Lim B, Karuturi MS, Tripathy D, Ueno NT
doi: 10.1001/jamaoncol.2016.4975.
Genitourinary Cancer
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
J Clin Oncol.
Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, Silberstein JL, Taylor MN, Maughan BL, Denmeade SR, Pienta KJ, Paller CJ, Carducci MA, Eisenberger MA, Luo J
doi: 10.1200/JCO.2016.70.1961.
Breast Cancer
Recent Developments in Metastatic Breast Cancer
healthbook TIMES Oncology Hematology
COMMENTED
Genitourinary Cancer
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
N Engl J Med.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR, ARAMIS Investigators.
doi: 10.1056/NEJMoa2001342.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lung Cancer.
Shi R, Filho SNM, Li M, Fares A, Weiss J, Pham NA, Ludkovski O, Raghavan V, Li Q, Ravi D, Cabanero M, Moghal N, Leighl NB, Bradbury P, Sacher A, Shepherd FA, Yasufuku K, Tsao MS, Liu G
doi: 10.1016/j.lungcan.2020.05.018.
Breast Cancer
Breast Cancer Treatment in the Era of Precision Medicine
1Breast Cancer Center, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland